Imcyse SA

Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies with an initial focus on severe autoimmune diseases. Imcyse’s proprietary ImotopeTM platform has the potential to address a wide range of diseases with a long-lasting and potentially curative effect. With a lead compound in Type 1 diabetes (T1D), a number of pre-clinical programs including major and rare indications and the first strategic partnership with Pfizer Inc. to progress the development of an ImotopeTM to treat rheumatoid arthritis (RA), Imcyse has created a diverse development and commercialization strategy, striving for five clinical stage programs by 2024.

Imcyse is member of INNODIA, a global network bringing their knowledge and experience together to fight T1D.


Imcyse at a glance:

Field of Activity Imcyse’s current autoimmune programs are in the fields of T1D, multiple sclerosis (MS), RA, neuromyelitis optica and celiac disease.
Ownership Structure and Financing Privately held. Shareholders include Pfizer, Biogenosis, Epimede, SRIW, SFPI and KU Leuven. Non-dilutive funding support provided from the Walloon region of Belgium and EU (FP7).
Technology Modified peptides – ImotopesTM – block immune-mediated diseases through specific and sustained destruction of the immune cells that are causing the disease, while leaving the remainder of the immune system unaffected. The technology is designed to stop an autoimmune response at a time before significant damage has occurred and to be used in combination with current treatments.
Products/Services The Company’s robust pipeline currently consists of 1 clinical and 4 pre-clinical programs. Imcyse’s most advanced drug is the insulin-based candidate for T1D, which is recruiting patients in the phase 2 IMPACT study and has had promising results seen during the first clinical trial. A clinical study in MS is expected to start in early 2022.
Unique Selling Point Safe, convenient and easy to manufacture: as Imotopes™ are derived from the protein, which is causing the disease, they are absolutely specific and leave the rest of the immune system functioning unaltered.
Long-lasting: The treatment benefit of lmotopes™ is long-lasting and daily treatment is not required.
Date of Incorporation/
Number of Employees 
2011/40

 


Contact:

Denis Bedoret Ph.D.,
Chief Executive Officer
Address Avenue du Pré-Aily 14
4031 Liège
Belgium
Telephone +32 4 325 11 00
URL www.imcyse.com